<DOC>
	<DOCNO>NCT00345644</DOCNO>
	<brief_summary>The primary objective study compare risedronate 35 mg placebo respect percent change 12 month distal radius trabecular bone volume ( BV/TV ) osteopenic postmenopausal woman , measure three-dimensional peripheral quantitative compute tomography ( 3D pQCT ) . The secondary objective compare percent change Screening/Baseline 2 treatment group follow measurement : - Bone mineral density lumbar spine , femoral neck , femoral trochanter , total proximal femur use dual energy X-ray absorptiometry ( DXA ) scan 12 24 month ; - 3D pQCT analysis distal radius distal tibia bone microarchitecture data 6 , 12 , 24 month ; - Bone turnover marker ( BTMs ) : - fast serum carboxyterminal cross link telopeptide type 1 bone collagen ( CTX 1 ) ; - serum aminoterminal propeptide type 1 procollagen ( PINP ) ; - urine N-telopeptide cross-link ( NTX ) 3 , 6 , 12 , 24 month .</brief_summary>
	<brief_title>Risedronate Osteopenic Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Osteopenic , postmenopausal woman , 55 75 year age body mass index ( BMI ) &lt; 30 kg/mÂ² Clinical radiological evidence osteoporosis Severe renal impairment Serum 5hydroxy vitamin D level &lt; 15 ng/ml History recent primary hyperparathyroidism recent thyroid disorder History generalize bone disease Current use glucocorticoid , estrogen , progestin , calcium supplement &gt; 1 g/day , vitamin D supplement &gt; 800 IU/day , parathyroid hormone ( PTH ) , bisphosphonate &gt; 1 month time within past 6 month . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Postmenopausal</keyword>
</DOC>